Conclusions
In this analysis of 17,524 OHT recipients, we demonstrate that the institutional utilization of induction therapy is highly variable across transplant centers and not necessarily attributable to differences in patients’ baseline rejection risk. Furthermore, other unmeasured center-level factors appear to contribute to differences in 1-year rejection rates to a higher degree than induction therapy use. The identification of such factors and efforts to better standardize induction therapy use in OHT appear prudent.